Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + nab-paclitaxel + carboplatin for neoadjuvant treatment of triple-negative breast cancer
ChiCTR2100041675Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Feb 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tislelizumab, paclitaxel and carboplatin in triple-negative breast cancer (TNBC), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Pathological complete response rate in all patients. Started Feb 2021; status: recruiting.
02
Drugs
tislelizumabpaclitaxelcarboplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2100041675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100041675.